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The biosynthesis and biological properties of the envelope glycoprotein from a primary isolate of the human immunodefi-
ciency virus type 1, HIV-1 YU2, and the Env product from the laboratory-adapted strain, HIV-1 LAI were compared in the
absence of viral replication. We found that the level of expression and proteolytic processing into gp120/gp41 complexes
of both glycoproteins was equivalent and independent of the cell type used. Although the two glycoproteins were detected
on the surface of HeLa cells expressing high levels of CD4, only the HIV LAI Env product induced significant syncytium
formation. Interestingly, when both glycoproteins were coexpressed in HeLa-CD4 cells, syncytium formation was greatly
reduced. However, cell fusion could be restored by increasing amounts of the LAI envelope gene product. HeLa-CD4 cells
expressing either glycoprotein fused with high efficiency to CEM-A cells, a hybrid of CEM and peripheral blood mononuclear
cells, indicating that both glycoproteins were expressed in a biologically active form on the surface of these cells. These
studies suggest that primary isolates and laboratory adapted strains may require, in addition to the CD4 receptor, independent
accessory membrane components for the fusion activation step. Our results agree with the concept that virus entry requires
the concerted activation of each glycoprotein subunit of the Env oligomeric complex. q 1996 Academic Press, Inc.
The entry of enveloped viruses into susceptible cells strains of HIV-1 are particularly sensitive to neutralization
by recombinant soluble CD4 (sCD4). Significantly higherbegins with the interaction of a viral glycoprotein and a
cellular receptor. This interaction leads to a series of concentrations of sCD4 are required for neutralization of
primary isolates (25 – 27). The major neutralization do-poorly understood events, the fusion activation steps,
which culminate with the coalescence of the viral and main of gp120, the V3 loop, confers tropism for entry of
specific CD4-positive cells and somehow contributes tocellular membranes and the incorporation of the nucleo-
capsid into the cytosol (35). In the case of the human the syncytium-forming capacity of the HIV glycoprotein
complex (15, 20). The mechanism(s) by which the V3 loopimmunodeficiency virus (HIV), the envelope glycoprotein
complex and the cellular receptor CD4 are the essential influences these different functions is not well under-
components of the entry process (14, 19, 21, 22, 37). stood. It has been suggested that binding of the V3 loop
However, it has been well documented that in certain to molecules that are accessories to CD4 would be a
cases, the interaction of CD4 with the HIV envelope gly- prerequisite of the fusion activation step. The cell surface
coprotein is not sufficient to permit viral entry (10, 11). In expression of such molecules could define cellular per-
addition, the diversity of HIV isolates and the marked missiveness and tropism for HIV.
differences in their capacity to infect CD4-positive cells To better understand the limiting steps of viral entry
such as macrophages or leukemic T-cells, make this for different HIV isolates in culture conditions, we ana-
entry process more difficult to understand. Typically, HIV lyzed the biological properties of the envelope glycopro-
isolates obtained during early asymptomatic stages of tein complex from a primary isolate of HIV-1, YU2, with
AIDS replicate in macrophages, do not induce syncytia a marked tropism for macrophages, and the laboratory-
in cell culture, and are not transmissible to cell lines. With adapted HIV-1 strain, LAI, in the absence of other struc-
the progression of AIDS symptoms, syncytium-inducing tural genes. The YU2 strain of HIV-1 is a primary isolate
strains appear that can grow in permanent cell lines but obtained by direct cloning of proviral DNA from uncul-
cannot infect macrophages (7, 29). tured brain from a patient with AIDS dementia complex
The affinity of gp120 for the CD4 receptor varies ac- (24). The characterization of the biological properties of
cording to the strain. In general, laboratory-adapted this isolate has contributed to the understanding of the
characteristics of HIV-1 viruses not previously subjected
to in vitro selection pressures. To study the biological1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (813) 577-9862. properties of the YU2 envelope protein in the absence
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FIG. 1. Top panel, Schematic diagram of the expression vectors for the HIV-1 primary isolate, YU2, and laboratory-adapted strain, LAI, envelope
glycoproteins. To construct pYU2Env, the restriction fragment Sal I–XhoI containing the coding sequences for the envelope gene of the LAI was
replaced in pwtEnv with the fragment EcoRI–XhoI containing the env sequences of the YU2 isolate. Both expression plasmids contain the SV40
origin of replication, and a pBR322 fragment including the origin of replication and the ampicillin resistant gene (28). Bottom panel, HIV-1 glycoproteins
expression from vectors pwtEnv and pYU2 in COS-1 and HeLa-CD4 cells. Cells were electroporated with either the pYU2Env or pwtEnv plasmids
(15 mg DNA/3 1 106 cells) and lysates prepared 48 hr later. Aliquots of the cell lysates (30 mg total protein/lane) were separated by SDS–PAGE
and the proteins electrotransferred to an Immun-Lite blotting membrane (Bio-Rad Laboratories, Richmond, CA). The blots were incubated with
human HIV-positive serum or a mouse monoclonal antibody directed against the carboxyl terminus of the gp120 subunit of the HIV-1 glycoprotein
(mAb 20-2-C85F3, Chiron, Emeryville, CA). Blots were developed with the ECL chemiluminescent substrate kit from Amersham (Amersham, UK)
followed by 10 sec autoradiography. Lane A, COS-1 cells transfected with pYU2Env; Lanes B and H, HeLa-CD4 cells transfected with pYU2Env;
Lane C, COS-1 cells mock transfected; Lane D, COS-1 cells transfected with pwtEnv; Lanes E and G, HeLa-CD4 transfected with pwtEnv; Lanes F
and I, HeLa-CD4 mock transfected.
of other viral structural genes, we constructed the eukary- simian virus 40 (SV40) T antigen. Nevertheless, cell ly-
sates from COS-1 and HeLa-CD4 cells transfected withotic transient expression system shown in Fig. 1. The
Sal I – XhoI restriction fragment in the expression system pwtEnv or pYU2Env show similar results (Fig. 1, bot-
tom). Protein bands corresponding to the precursorfor the LAI envelope glycoprotein, pwtEnv (28), was re-
placed with the restriction fragment EcoRI – XhoI from (gp160), the SU protein (gp120), and the TM protein
(gp41) were detected with an HIV-1-positive serum inthe YU2 infectious clone, pTZ 19R (24), to generate the
expression plasmid pYU2Env (same Fig. 1). In both ex- COS-1 cells transfected with pwtEnv (Fig. 1, bottom
panel, lanes D and E). Comparable protein levels werepression plasmids, the envelope glycoprotein genes are
under the control of the same HIV-1 viral LTR promoter. detected in cell lysates obtained from COS-1 cells
electroporated with pYU2Env (Fig. 1, bottom panel,The biosynthesis and processing of the primary
translation product of the YU2 env gene was compared lanes A and B). In HeLa-CD4 cells the SU/gp120 sub-
unit was not detectable with the human serum; how-with that of the LAI isolate in two mammalian cell lines.
COS-1 and HeLa-CD4 cells were electroporated with ever, this protein was detected in these cells with a
mouse monoclonal antibody against a conserved do-the plasmid expression vectors pYU2Env and pwtEnv,
and the envelope glycoproteins were detected in the main of the carboxyl-terminus of gp120 (Fig. 1, bottom
panel, lanes H and G). In this Western blot analysis,cell lysates by Western blot analysis. Despite similar
transfection efficiencies (5%), the protein expression the YU2 Env precursor and the SU/gp120 subunits
were found to migrate slightly faster than the LAI coun-levels were significantly higher in COS-1 cells due to
the amplification of the expression vectors by the terparts. This differential migration in SDS – PAGE gels
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the cell lines used in this study, comparable levels of
both the YU2 and LAI glycoproteins are expressed and
transported to the cell surface.
Previously, it has been shown that primary HIV iso-
lates, including the YU2 isolate, have a high tropism for
macrophages but cannot infect HeLa-CD4 cells or T-cell
leukemia cells (4, 5, 16, 24, our unpublished results). To
determine the basis of this restriction in viral entry, we
compared the syncytium-forming capacity of the YU2 Env
protein with the LAI env product in the absence of viral
infection. A HeLa cell line that expresses high levels of
the human CD4 receptor and a transactivable Esche-
richia coli b-galactosidase enzyme was chosen for this
study. In this system, the transfected plasmid that ex-
presses the env gene also encodes the Tat protein which
transactivates b-gal expression. b-galactosidase accu-
mulates in the nucleus due to the presence of a nuclear
transport signal. As shown in Fig. 3A, the expression of
the LAI envelope glycoprotein resulted in very efficient
syncytium formation (over 50% of the cells with blue nu-
clei), while that of the YU2 glycoprotein or a plasmid
expressing only the Tat protein resulted in only blue mo-
nonucleated cells (Figs. 3B and 3F, respectively). These
results demonstrate that expression of the YU2 envelope
glycoprotein and the presence of the CD4 receptor are
not sufficient to promote significant syncytium formation
in this HeLa cell line. When HeLa-CD4 cells were
transfected with equal amounts of the expression plas-
mids for the YU2 and LAI glycoproteins less than 1% of
the cells with blue nuclei were multinucleated (Fig. 3C).
When the indicator cell line was transfected with a ratio
of YU2 to LAI plasmid DNA of 1:4, the percentage ofFIG. 2. Cell surface expression of the YU2 and LAI glycoproteins in
syncytia with blue nuclei was increased to about 35%COS-1 cells. At 48 hr postelectroporation, COS-1 cells grown on cover
(Fig. 3D). By contrast, approximately 3% of the cells withslips were washed with cold PBS-BSA and incubated with HIV-1-posi-
tive human serum followed by a FITC-labeled antihuman antibody at blue nuclei were found to form syncytia when cells were
47. After final washes the cells were fixed with 95% ethanol, 5% acetic transfected with a ratio of YU2 to LAI plasmid of 4:1 (Fig.
acid on the coverslips, and mounted for observation. The figure show 3E). On the other hand, coexpression of the envelopesingle cells photographed with automatic exposure (magnification, at
glycoprotein of the lymphotropic HIV-1 isolate HXB2, us-401).
ing the plasmid pIII env 3-1, and the LAI Env product
(DNA ratio 1:1) resulted in efficient syncytium formation
(Fig. 3H). These results indicate that coexpression ofhas been previously observed with the envelope glyco-
proteins of this and other primary isolates (18, 32). the YU2 glycoprotein and LAI Env product results in an
inhibition of the syncytium-forming capacity of the latterWe conclude from these results that both envelope
glycoprotein precursors were expressed and proteolyt- glycoprotein in HeLa-CD4 cells. To demonstrate that the
YU2 envelope glycoprotein complex was expressed in aically processed with similar efficiencies in the cell
types studied. biologically active form on the surface of the HeLa-CD4
cells, the following experiment was performed. HeLa-Indirect immunofluorescence was used to detect cell
surface expression of these viral glycoproteins on the CD4 cells transfected with the YU2 or the LAI glycopro-
tein expression plasmids were overlaid with the cell linecell membrane of the transfected COS-1. As shown in
Fig. 2, staining with a HIV-1-positive serum resulted in CEM-A, a fusion product of CEM and PBMCs (34). Effi-
cient syncytium formation was observed between HeLa-comparable levels of cell surface immunofluorescence
in cells transiently expressing either the YU2 (pYU2Env) CD4 expressing the LAI glycoprotein and CEM-A cells
(Fig. 4A). Similar results were obtained when CEM-Aor the LAI envelope (pwtEnv) glycoproteins, but not on
cells transfected with a Tat plasmid (control). Similarly, cells were added to HeLa-CD4 cells expressing the YU2
env gene product (Fig. 4B). As shown in Fig. 4C, no spon-both glycoprotein complexes could be biotinylated on the
surface of HeLa-CD4 cells expressing these env genes taneous fusion was observed between the two cell types
used in this study. These results demonstrate that the(data not shown). These results indicate that in each of
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FIG. 3. Biological activity of the LAI and YU2 envelope gene products in HeLa-CD4 cells. 3 1 106 HeLa-CD4-b-Gal cells (17) were electroporated
with a total of 20 mg of DNA. X-Gal staining was performed 48 hr as described previously (17, 28). (A) Cells transfected with pwtEnv only, (B) cells
transfected with pYU2Env only, (C) cells transfected with a pwtEnv to pYU2Env DNA ratio of 1:1, (D) cells transfected with a ratio of YU2 to LAI
plasmid DNA of 1:4, (E) cells transfected with a pYU2 to pwtEnv DNA ratio of 4:1, (F) cells electroporated with pTat only (13), (G) cells electroporated
with a pIII env 3-1 to pwtEnv DNA ratio 1:1, (H) mock-transfected cells.
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other subunit, SU/gp120 (1, 14, 15). It has been suggested
that the V3 loop binds to a molecule or a family of mole-
cules which are accessories to CD4 (23). The particular
cellular distribution of such molecules would determine
cell tropism for HIV. In addition, the interaction of V3 with
these accessory molecules would result in the exposure
of the TM fusion domain, which would promote the viral
and cell membrane mixing. The results presented here
suggest the involvement of such accessory molecules
in HIV glycoprotein-mediated cell fusion. Evidence that
accessory molecules have a particular cell distribution
comes from our findings that the envelope glycoproteins
of primary isolates do not induce syncytia when ex-
pressed in HeLa-CD4 cells. However, HeLa-CD4 ex-
pressing these Env products are capable of fusing effi-
ciently to heterocaryons of CEM and PBMC cells, but not
to CEM cells (data not shown). The use of only the HIV-1
viral glycoproteins in our studies, rules out the inefficient
adsorption of HIV viral particles onto HeLa CD4 cells, a
phenomenon observed in previous studies (16). We
found that both the YU2 and LAI glycoproteins were ex-
pressed, processed, and transported efficiently to the
cell surface (Fig. 2). Thus, we could not detect defects
in any of these steps of the biosynthetic pathway that
might account for the different phenotypes of these Env
products in HeLa-CD4 cells. Since the fusion indicator
cell line used in this study expresses high levels of CD4
(data not shown), it is unlikely that higher levels of the
CD4 receptor could be required for the fusion activation
of the YU2 envelope protein in this particular HeLa cell
clone. The fusogenic selectivity of the glycoproteins of
primary and laboratory-adapted strains used here sug-
gests that not all HIV variants would use the same acces-
sory molecules for cell entry. Similar characteristics were
described for another HIV-1 primary isolate (31). Using
the macrophage-tropic HIV-1 strain, 89.6, Stefano and
coworkers demonstrated that this primary isolate could
infect the T-cell/B-cell hybrid line, CEMx174, but not the
FIG. 4. Syncytium formation between HeLa-CD4 cells expressing the parental T-cell line CEM.3. Since CEMx174 cells were
YU2 and LAI glycoproteins and CEM-A cells. HeLa-CD4 cells were
resistant to other primary isolates, this group suggestedtransfected with 20 mg of the YU2 or LAI expression plasmids and
the existence of HIV strain-specific accessory factors,plated in 60-mm dishes. After 24 hr 4 1 105 CEM-A cells, were overlaid
on the transfected HeLa cells and the plates incubated for another 24 which would facilitate entry into CD4-positive cells. Our
hr. After this incubation period, the cells were fixed and stained with study with only viral glycoproteins substantiates this pre-
X-Gal to visualize the multinucleated cells. (A) HeLa-CD4 expressing vious observation.
the LAI glycoprotein, (B) HeLa-CD4 expressing the YU2 Env products,
Coexpression of mutants and wild-type env products(C) Mock-transfected HeLa-CD4 cell.
of the vesicular stomatitis virus glycoprotein (G), have
demonstrated that G trimers are in a dynamic equilibrium
with G monomers in the endoplasmic reticulum and sug-syncytium-forming capability of the YU2 envelope glyco-
protein expressed on HeLa-CD4 cell membranes can be gests that this is probably a general phenomenon for
oligomeric proteins (38). The lack of syncytium formationactivated by an interaction with CEM-A cells.
The understanding of the fusion activation steps that observed during coexpression of the YU2 and LAI glyco-
proteins could be the result of the formation of heterooli-follow the initial binding of the Env glycoprotein complex
to the CD4 receptor is essential to reveal the mechanism gomers of envelope glycoprotein monomers that require
different accessory molecules for the fusion activationof HIV entry into CD4-positive cells. Two distinct domains
of the HIV envelope glycoprotein have been implicated step. Unfortunately, we do not have the means to resolve
between heterooligomers and homooligomers of the twoin this process, namely the N-terminal fusion peptide of
the TM/gp41 subunit and the V3 loop located on the HIV-1 envelope products used in this study. However,
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